NASDAQ
7.06USD
-1.85 (-20.76%)
We have scored 11 news catalysts on Jaguar Health, Inc. (JAGX) over the past 12 months. The biggest single-day move next to one of them came Sep 24, 2026, when JAGX closed −20.8%: “Jaguar Health Stock Slides Thursday: What's Happening?”. Coverage across the window leans positive (average ticker sentiment +0.39). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.1M
P/E
—
EPS
—
Beta
-0.05
52W range
2.35-1281
Day range
6.02–7.72
Open
7.03
Prev close
8.91
Volume
2M
Avg volume
462.8K
Dividend
0.00
IPO
2015-05-12
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Jaguar Health, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Jaguar Health, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for JAGX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.
